Cancer care and reimbursement are changing, according to the keynote address, “Ensuring Quality Care for Each Patient: How Legislative and Regulatory Changes May Impact Community Oncology,” at the 2014 Association of Community Cancer Centers’ 40th annual meeting.
Challenges come from all directions, and good oncology managers have eyes in the backs of their heads. Two significant challenges arose recently, stemming from a common computer operating system platform as well as from the US government.
As physicians, nurses, and practice managers continue to adapt to an ever-changing landscape, healthcare disruptions affecting providers, payers, and patients have become the status quo. During a recent oncology conference, thought-leader panelists advised participants to expect the unexpected, not just in oncology, but in the medical system as a whole.
On April 29, 2014, the US Food and Drug Administration (FDA) approved ceritinib (Zykadia; Novartis) for the treatment of patients with metastatic, anaplastic lymphoma kinase (ALK)-positive non–small-cell lung cancer (NSCLC).
Quite often I am asked what constitutes “good” oncology care. Many people have their opinions; patients, doctors, allied medical professionals, and even health plan administrators like to weigh in on this issue...
We see a number of changes physicians might make to improve their financial security, but 1 item is usually beyond their control: the 401(k) plan. Unless you are self-employed, there is practically nothing you can do about your 401(k)’s underwhelming investment options, ridiculously low contribution limits, or perverse tax consequences.
As they navigate payer requirements, practices and care facilities find that they are able to reach their highest standard of documentation and billing compliance only by applying focused effort and dedicated resources.
The 2014 Association of Community Cancer Centers (ACCC) Annual National Meeting brought together oncology care providers from across the country to network and learn about the legislative and regulatory policies impacting cancer care—and the timing could not have been better. Members in attendance at the meeting, held March 31 to April 2, were present for an important congressional vote on the sustainable growth rate (SGR) formula, and even celebrated a victory with the passage of oral parity legislation in Wisconsin.
The following clinical trials are currently recruiting patients with colorectal cancer for inclusion in several investigations. Each trial description includes the NLM Identifier to use as reference with Clinical Trials.gov.
The following sections will assist healthcare professionals and payers by providing appropriate coding and billing information associated with the treatment of colorectal cancer.
Results 1 - 10 of 10